

LIVE FOR MORE WINNING HANDS

IMBRUVICA[®] gives patients with 1L CLL/SLL an **OPPORTUNITY TO LIVE LONGER** and continue to experience the things they love^{2,3}

PRIMARY ANALYSIS:

- Estimated 18-month PFS was 90% with IMBRUVICA[®] vs 52% with chlorambucil, HR=0.16 (95% CI: 0.09, 0.28; $P < 0.0001$; PFS was the primary endpoint)
- Estimated 2-year OS was 95% with IMBRUVICA[®] (95% CI: 89, 97) vs 84% with chlorambucil (95% CI: 77, 90), HR=0.44 (95% CI: 0.21, 0.92; OS was the secondary endpoint)

INDICATIONS

IMBRUVICA[®] is a kinase inhibitor indicated for the treatment of:

- Adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage; infections; cardiac arrhythmias, cardiac failure, and sudden death; hypertension; cytopenias; second primary malignancies; hepatotoxicity, including drug-induced liver injury (DILI); tumor lysis syndrome; and embryo-fetal toxicity.

ADVERSE REACTIONS

The most common adverse reactions ($\geq 30\%$) in patients with B-cell malignancies were thrombocytopenia (55%)*, diarrhea (44%), fatigue (39%), musculoskeletal pain (39%), neutropenia (39%)*, rash (36%), anemia (35%)*, bruising (32%), and nausea (30%).

*Treatment-emergent decreases (all grades) were based on laboratory measurements.

Please see complete Important Safety Information on pages 10-11 and [click here](#) for full Prescribing Information.

1L=first-line, CI=confidence interval, CLL=chronic lymphocytic leukemia, HR=hazard ratio, OS=overall survival, PFS=progression-free survival, SLL=small lymphocytic lymphoma.

THE ONLY
BTKi

with up to 10 years of
long-term follow-up¹


imbruvica[®]
(ibrutinib)

420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension

RESONATE™-2: STUDY DESIGN AND SELECT BASELINE CHARACTERISTICS¹⁻⁵

Study design

Randomized, multicenter, open-label, phase 3 RESONATE™-2 trial (N=269)^{2,3}



PFS was assessed by an IRC per iwCLL criteria (primary analysis)²

- Median follow-up for 10-year update of RESONATE™-2 was 9.6 years (115.0 months [range: 0.1–122.8 months]) for patients in the IMBRUVICA® arm for all efficacy endpoints^{1,4}
- 27% of patients (37/136) continued IMBRUVICA® treatment at the median follow-up of 9.6 years (115.0 months, range: 0.1–122.8 months)^{1,4}
- The median duration of IMBRUVICA® treatment was 6.2 years (range, 0.06–10.2)¹

RESONATE™-2 included patients with select high-risk characteristics^{2,3,5}

Select patient characteristics



IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: Fatal bleeding events have occurred in patients who received IMBRUVICA®. Major hemorrhage (≥ Grade 3, serious, or any central nervous system events; e.g., intracranial hemorrhage [including subdural hematoma], gastrointestinal bleeding, hematuria, and post procedural hemorrhage) occurred in 4.2% of patients, with fatalities occurring in 0.4% of 2,838 patients who received IMBRUVICA® in 27 clinical trials. Bleeding events of any grade including bruising and petechiae occurred in 39%, and excluding bruising and petechiae occurred in 23% of patients who received IMBRUVICA®, respectively.

*Patients on chlorambucil were able to cross over to IMBRUVICA® after IRC-confirmed disease progression.

**Patients with IRC-confirmed progressive disease were enrolled in an extension study for follow-up and collection of long-term safety and efficacy data and to allow for second-line treatment per investigator's choice (including IMBRUVICA® for patients progressing on chlorambucil per iwCLL criteria).

CLL=chronic lymphocytic leukemia, del=deletion, ECOG=Eastern Cooperative Oncology Group, IGHV=immunoglobulin heavy-chain variable region gene, IRC=independent review committee, iwCLL=International Workshop on Chronic Lymphocytic Leukemia, ORR=overall response rate, OS=overall survival, PFS=progression-free survival, PS=performance status, SLL=small lymphocytic lymphoma.

imbruvica®
(ibrutinib)

420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension

LIVING LONGER IN 1L CLL^{2,3}

RESONATE™-2 primary analysis^{*†}

OS (secondary endpoint)²



Estimated 2-year OS rate
with IMBRUVICA®
(95% CI: 89, 97)

VS



with chlorambucil (95% CI: 77, 90)

- Median follow-up of 28.1 months
- HR: 0.44 (95% CI: 0.21, 0.92)
- 41% of chlorambucil-treated patients crossed over to IMBRUVICA® upon disease progression

PFS (IRC-assessed primary endpoint)²



Estimated 18-month PFS rate
with IMBRUVICA®

VS



with chlorambucil

- Median follow-up of 18.4 months
- Median PFS with IMBRUVICA® was not estimable vs 18.9 months (95% CI: 14.1, 22.0) with chlorambucil
- HR=0.16 ([95% CI: 0.09, 0.28]; $P<0.0001$)

Most common ARs reported in the primary analysis of RESONATE™-2 (median duration of exposure to IMBRUVICA®: 17.4 months, n=135)²

- The most common ARs (all grades) occurring in $\geq 15\%$ of patients receiving IMBRUVICA® were neutrophils decreased (55%), platelets decreased (47%), diarrhea (42%), hemoglobin decreased (36%), musculoskeletal pain[‡] (36%), fatigue (30%), cough (22%), nausea (22%), rash[‡] (21%), bruising[‡] (19%), peripheral edema (19%), dry eye (17%), pyrexia (17%), upper respiratory tract infection (17%), arthralgia (16%), constipation (16%), and skin infection[‡] (15%)
- The most common ($\geq 5\%$) ARs (grades ≥ 3) occurring in patients receiving IMBRUVICA® were neutrophils decreased[§] (28%), pneumonia[‡] (8%), platelets decreased[§] (7%)

*Patients on chlorambucil were able to cross over to IMBRUVICA® after IRC-confirmed disease progression.

†Patients with IRC-confirmed progressive disease were enrolled in an extension study for follow-up and collection of long-term safety and efficacy data and to allow for second-line treatment per investigator's choice (including IMBRUVICA® for patients progressing on chlorambucil per iwCLL criteria).

‡Includes multiple ADR terms.

§Grade 3-4 for laboratory abnormalities.


1L=first-line, ADR=adverse drug reaction, AR=adverse reaction, CI=confidence interval, CLL=chronic lymphocytic leukemia, HR=hazard ratio, IRC=Independent Review Committee, OS=overall survival, PFS=progression-free survival.

imbruvica[®]
(ibrutinib)

420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension


THE ONLY BTKi WITH UP TO 10 YEARS OF FOLLOW-UP DATA^{1,4}

Estimated OS was 68% at 9 years with IMBRUVICA[®]^{1,4}



- Median OS was not reached in the IMBRUVICA[®] arm¹
- Median follow-up for patients in the IMBRUVICA[®] arm for all efficacy endpoints was 9.6 years (115.0 months [range 0.1–122.8])^{1,4}

Estimated PFS was 50% at 9 years with IMBRUVICA[®] vs 4% with chlorambucil^{1,4}



- With up to 10 years of follow-up, median PFS for IMBRUVICA[®] was 8.9 years (95% CI: 7.0, NE) vs 1.3 years (95% CI: 0.9–1.6) with chlorambucil¹
- For patients in the chlorambucil arm, median follow-up was 5.6 years (66.7 months [range 0.1–118.4 months])^{1,4}
- Median follow-up for patients in the IMBRUVICA[®] arm for all efficacy endpoints was 9.6 years (115.0 months [range 0.1–122.8])^{1,4}

10-year RESONATE™-2 long-term efficacy results are not included in the Prescribing Information for IMBRUVICA[®]. The timing for long-term follow-up was not prespecified, and the analysis was descriptive in nature.

HR=hazard ratio, NE=not evaluable, OS=overall survival, PD=progressive disease, PFS=progression-free survival.

imbruvica[®]
(ibrutinib)


420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension

UP TO 10 YEARS OF FOLLOW-UP INCLUDING IN PATIENTS WITH CERTAIN HIGH-RISK MUTATIONS^{4,6}


Discover the long-term OS data for your patients with high-risk mutations, including *TP53* mutation, del11q, and unmutated IGHV⁴

- RESONATE™-2 was not designed to test treatment effect in subpopulations and was not powered to show statistical differences among these subgroups
- Subgroup analysis was not prespecified, is descriptive, and is not included in the USPI
- No subgroups were adjusted for multiplicity, and there is no *P* value
- Patients with del17p were excluded from the trial

Descriptive subgroup OS analysis in high-risk groups⁴



Primary analysis: forest plot⁶



65%

OS

ESTIMATED 9-YEAR OS RATE WITH IMBRUVICA®, *TP53* MUTATION, DEL11q, AND UNMUTATED IGHV

- Median follow-up of high-risk group LTFU RESONATE™-2 was 9.6 years (115.0 months; range, 0.1–122.8)

Most common treatment-emergent ARs across 10 years at the long-term analysis reported in RESONATE™-2 for the overall population (n=135)⁴

- The most common ARs (all grades) occurring in $\geq 20\%$ of patients receiving IMBRUVICA® were diarrhea (52%), fatigue (41%), cough (39%), nausea (32%), arthralgia (31%), peripheral edema (31%), hypertension (30%), pyrexia (30%), upper respiratory tract infection (30%), pneumonia (29%), anemia (27%), urinary tract infection (26%), weight loss (25%), atrial fibrillation (24%), constipation (23%), vomiting (22%), back pain (21%), fall (21%), muscle spasms (21%), and dry eye (20%).
- The most common ARs (grade ≥ 3) occurring in $\geq 5\%$ of patients receiving IMBRUVICA® were pneumonia (20%), neutropenia (13%), hypertension (12%), anemia (7%), cataract (7%), hyponatremia (7%), atrial fibrillation (6%), syncope (6%), diarrhea (5%) and cardiac failure (5%).

10-year RESONATE™-2 long-term data are not included in the Prescribing Information for IMBRUVICA®. The timing for long-term follow-up was not prespecified, and the analysis was descriptive in nature.

AR=adverse reaction, BTKi=Bruton's tyrosine kinase inhibitor, CI=confidence interval, del=deletion, HR=hazard ratio, IGHV=immunoglobulin heavy-chain variable region gene, LTFU=long-term follow-up, OS=overall survival, PD=progressive disease, PFS=progression-free survival, uIGHV=unmutated immunoglobulin heavy-chain variable region gene.

imbruvica®
(ibrutinib)

420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension

POOLED 5-YEAR LONG-TERM SAFETY DATA^{2,7,8}


Long-term safety²

In a long-term safety analysis over 5 years of 1,284 patients with B-cell malignancies treated for a median of 36 months (range, 0 to 98 months), the cumulative rate of hypertension increased over time. The prevalence for Grade 3 or greater hypertension was 4% (year 0–1), 7% (year 1–2), 9% (year 2–3), 9% (year 3–4), and 9% (year 4–5); the overall incidence for the 5-year period was 11%.

5-year, long-term safety from CLL/SLL studies^{7*}

In pooled data from multiple open-label rollover and follow-up studies in both treatment-naïve and R/R CLL/SLL patients (N=808), the median treatment duration was 51 months (range, 0.2 to 98 months). Due to types of events collected and less frequent clinic visits, limited data were collected from 1 follow-up study.

Most common treatment-emergent ARs (any grade) in ≥20% of patients with CLL/SLL (N=808)^{7,8}



*Additional safety analysis conducted pursuant to FDA postmarketing requirements.
[†]Includes multiple preferred terms.

Data suggest AR rates generally decreased or remained stable over time, except for hypertension

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Hemorrhage (cont'd): The mechanism for the bleeding events is not well understood.

Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA[®] increases the risk of major hemorrhage. Across clinical trials, 3.1% of 2,838 patients who received IMBRUVICA[®] without antiplatelet or anticoagulant therapy experienced major hemorrhage. The addition of antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4%, and the addition of anticoagulant therapy with or without antiplatelet therapy increased this percentage to 6.1%. Consider the risks and benefits of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA[®]. Monitor for signs and symptoms of bleeding.

Consider the benefit-risk of withholding IMBRUVICA[®] for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

AR=adverse reaction, CLL=chronic lymphocytic leukemia, CNS=central nervous system, R/R=relapsed/refractory, SLL=small lymphocytic lymphoma.

imbruvica[®]
(ibrutinib)

420, 280, 140 mg tablets | 140, 70 mg capsules
 70 mg/mL oral suspension

DOSE MODIFICATIONS CAN HELP OPTIMIZE PATIENT MANAGEMENT TO ENABLE CONTINUED IMBRUVICA® TREATMENT WHERE APPROPRIATE²

IF AN AR LISTED BELOW OCCURS, INTERRUPT IMBRUVICA® THERAPY AT EACH OCCURRENCE OF THE SAME AR. ONCE THE AR HAS IMPROVED TO GRADE 1 OR BASELINE, FOLLOW THE RECOMMENDED DOSAGE MODIFICATIONS BELOW²

	ADVERSE REACTION*†	1 ST OCCURRENCE	2 ND OCCURRENCE	3 RD OCCURRENCE
CLL/SLL START at approved dose 420 mg once daily until disease progression or unacceptable toxicity	CARDIAC			
	• Grade 2: cardiac failure	↻ RESTART AT 280 mg [‡] DAILY	↻ RESTART AT 140 mg [‡] DAILY	⊘ DISCONTINUE
	• Grade 3: cardiac arrhythmias	↻ RESTART AT 280 mg [‡] DAILY	⊘ DISCONTINUE	
	• Grade 3 or 4: cardiac failure • Grade 4: cardiac arrhythmias	⊘ DISCONTINUE		
	NON-CARDIAC			
	• Grade 3 or 4: other non-hematological toxicities [§] • Grade 3 or 4: neutropenia with infection or fever • Grade 4: hematological toxicities	↻ RESTART AT 280 mg DAILY	↻ RESTART AT 140 mg DAILY	⊘ DISCONTINUE

*See full Prescribing Information for Warnings and Precautions (Section 5).

†Grading based on NCI-CTCAE criteria, or iwCLL criteria for hematologic toxicities in CLL/SLL.

‡Evaluate the benefit-risk before resuming treatment.

§For Grade 4 non-hematologic toxicities evaluate the benefit-risk before resuming treatment.

IMBRUVICA® monotherapy is dosed at 420 mg once daily until disease progression or unacceptable toxicity.²

Dose should be taken at approximately the same time each day. Do not open, break, or chew the capsules. Do not cut, crush, or chew the tablets.²

Modify dose or avoid IMBRUVICA® use with CYP3A inhibitors and avoid coadministration with strong CYP3A inducers.² For further information on use with CYP3A inhibitors and inducers, and in patients with hepatic impairment, please see the full Prescribing Information.

Consider the risks and benefits of anticoagulant or antiplatelet therapy when coadministered with IMBRUVICA®. Monitor for signs and symptoms of bleeding. Consider the benefit-risk of withholding IMBRUVICA® for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.²

Please see full Prescribing Information for complete dosage and administration details.

AR=adverse reaction, CLL=chronic lymphocytic leukemia, CYP3A=cytochrome P450, family 3, subfamily A, iwCLL=International Workshop on Chronic Lymphocytic Leukemia, NCI-CTCAE=National Cancer Institute-Common Terminology Criteria for Adverse Events, SLL=small lymphocytic lymphoma.

imbruvica®
 (ibrutinib)
 420, 280, 140 mg tablets | 140, 70 mg capsules
 70 mg/mL oral suspension

DOSE MODIFICATIONS FOR ARs: TREATMENT DURATION⁵

8-year dose modification⁵

Median overall duration of treatment



The median duration of IMBRUVICA[®] treatment was 74 months (range, 0.7–96.6 months; n=135)⁵

Duration of treatment following dose modification*



In a subset of patients who had dose reductions due to ARs (n=31), the median duration of treatment with IMBRUVICA[®] after the dose modification was 36.1 months (range, 0.0–84+ months)⁹

8-year RESONATE[™]-2 long-term dosing results are not included in the Prescribing Information for IMBRUVICA[®].

- These data are descriptive in nature only and have no implications regarding efficacy or safety
- Dose modifications were defined in the study protocol; patients may not have been dose modified according to current recommendations

IMBRUVICA[®] discontinuations across CLL/SLL registration studies²

The data below are pooled from 5 randomized controlled clinical trials (RESONATE[™], RESONATE[™]-2, HELIOS, iLLUMINATE[™], and E1912) and 1 single-arm, open-label clinical trial (Study 1102) in patients with CLL/SLL (N=2,016 total and n=1,133 patients exposed to IMBRUVICA[®]).

- 4% to 10% of patients receiving IMBRUVICA[®] discontinued treatment due to ARs
 - These included pneumonia, hemorrhage, atrial fibrillation, neutropenia, arthralgia, rash, and thrombocytopenia
 - ARs leading to dose reduction occurred in approximately 9% of patients

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Infections: Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA[®] therapy. Grade 3 or greater infections occurred in 21% of 1,476 patients with B-cell malignancies who received IMBRUVICA[®] in clinical trials. Cases of progressive multifocal leukoencephalopathy (PML) and *Pneumocystis jirovecii* pneumonia (PJP) have occurred in patients treated with IMBRUVICA[®]. Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections. Monitor and evaluate patients for fever and infections and treat appropriately.

*Duration of dose reduction to study drug discontinuation was calculated from first date of the earliest dose reduction to study drug discontinuation.

AR=adverse reaction, CLL=chronic lymphocytic leukemia, NE=not estimable, SLL=small lymphocytic lymphoma.


imbruvica[®]
(ibrutinib)

420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension

IMBRUVICA[®] HAS LONG-TERM OUTCOME DATA AFTER DOSE MODIFICATION^{9,10}

RESONATE[™]-2: Long-term analysis

Exploratory post hoc analysis: PFS in IMBRUVICA[®]-treated patients with or without dose modifications due to AEs⁹



This exploratory analysis evaluated baseline demographics and clinical outcomes (PFS) in subgroups of patients with and without dose reductions due to AEs from the overall population of IMBRUVICA[®]-treated CLL patients.⁹

- The median time to first dose reduction was 23.7 months (range, 1.6–78.4 months)¹⁰
 - Median PFS for IMBRUVICA[®]-treated patients with dose reductions was 87.7 months (95% CI: 56.9–NE) and was not reached (95% CI: 81.9–NE) for those without dose reductions⁹
 - Median follow-up was 82.7 months (range, 0.1–96.6 months)⁹
 - AEs led to dose reductions in 23% (31/135) of all patients treated with IMBRUVICA[®]
-
- Results are based on a starting dosage of IMBRUVICA[®] 420 mg once daily. Kaplan-Meier curves ≥ 7.5 years have a limited sample size, potentially impacting PFS estimates⁸
 - Subgroups of patients with and without dose modifications were not stratified for any baseline characteristics. Imbalances in baseline characteristics may exist between these groups⁸
 - Outcomes in the subgroup of patients with and without dose reductions in the overall population of all IMBRUVICA[®]-treated patients from RESONATE[™]-2 are from exploratory post hoc analyses and were not powered for significance; comparative statistics are provided for descriptive purposes only⁸
 - Dose modifications for any reason were per protocol based on the discretion of the physician⁸

8-year RESONATE[™]-2 long-term dosing results are not included in the Prescribing Information for IMBRUVICA[®]

AE=adverse event, CI=confidence interval, CLL=chronic lymphocytic leukemia, HR=hazard ratio, NE=not estimable, PFS=progression-free survival.

imbruvica[®]
(ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: Fatal bleeding events have occurred in patients who received IMBRUVICA®. Major hemorrhage (\geq Grade 3, serious, or any central nervous system events; e.g., intracranial hemorrhage [including subdural hematoma], gastrointestinal bleeding, hematuria, and post procedural hemorrhage) occurred in 4.2% of patients, with fatalities occurring in 0.4% of 2,838 patients who received IMBRUVICA® in 27 clinical trials. Bleeding events of any grade including bruising and petechiae occurred in 39%, and excluding bruising and petechiae occurred in 23% of patients who received IMBRUVICA®, respectively.

The mechanism for the bleeding events is not well understood.

Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA® increases the risk of major hemorrhage. Across clinical trials, 3.1% of 2,838 patients who received IMBRUVICA® without antiplatelet or anticoagulant therapy experienced major hemorrhage. The addition of antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4%, and the addition of anticoagulant therapy with or without antiplatelet therapy increased this percentage to 6.1%. Consider the risks and benefits of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA®. Monitor for signs and symptoms of bleeding.

Consider the benefit-risk of withholding IMBRUVICA® for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Infections: Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA® therapy. Grade 3 or greater infections occurred in 21% of 1,476 patients with B-cell malignancies who received IMBRUVICA® in clinical trials. Cases of progressive multifocal leukoencephalopathy (PML) and *Pneumocystis jirovecii* pneumonia (PJP) have occurred in patients treated with IMBRUVICA®. Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections. Monitor and evaluate patients for fever and infections and treat appropriately.

Cardiac Arrhythmias, Cardiac Failure, and Sudden Death: Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA®. Deaths due to cardiac causes or sudden deaths occurred in 1% of 4,896 patients who received IMBRUVICA® in clinical trials, including in patients who received IMBRUVICA® in unapproved monotherapy or combination regimens. These adverse reactions occurred in patients with and without preexisting hypertension or cardiac comorbidities. Patients with cardiac comorbidities may be at greater risk of these events.

Grade 3 or greater ventricular tachyarrhythmias were reported in 0.2%, Grade 3 or greater atrial fibrillation and atrial flutter were reported in 3.7%, and Grade 3 or greater cardiac failure was reported in 1.3% of 4,896 patients who received IMBRUVICA® in clinical trials, including in patients who received IMBRUVICA® in unapproved monotherapy or combination regimens. These events have occurred particularly in patients with cardiac risk factors including hypertension and diabetes mellitus, a previous history of cardiac arrhythmias, and in patients with acute infections.

Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function. Obtain further evaluation (e.g., ECG, echocardiogram) as indicated for patients who develop symptoms of arrhythmia (e.g., palpitations, lightheadedness, syncope, chest pain), new onset dyspnea, or other cardiovascular concerns. Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA® treatment.

Hypertension: Hypertension occurred in 19% of 1,476 patients with B-cell malignancies who received IMBRUVICA® in clinical trials. Grade 3 or greater hypertension occurred in 8% of patients. Based on data from a subset of these patients (N=1,124), the median time to onset was 5.9 months (range, 0 to 24 months). In a long-term safety analysis over 5 years of 1,284 patients with B-cell malignancies treated for a median of 36 months (range, 0 to 98 months), the cumulative rate of hypertension increased over time. The prevalence for Grade 3 or greater hypertension was 4% (year 0-1), 7% (year 1-2), 9% (year 2-3), 9% (year 3-4), and 9% (year 4-5); the overall incidence for the 5-year period was 11%. Monitor blood pressure in patients treated with IMBRUVICA®, initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA® as appropriate, and follow dosage modification guidelines for Grade 3 or higher hypertension.

Cytopenias: In 645 patients with B-cell malignancies who received IMBRUVICA® as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8%, and grade 3 or 4 anemia in 2.8%, based on laboratory measurements. Monitor complete blood counts monthly.

imbruvica®
(ibrutinib)

420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Second Primary Malignancies: Other malignancies (10%), including non-skin carcinomas (3.9%), occurred among the 1,476 patients with B-cell malignancies who received IMBRUVICA® in clinical trials. The most frequent second primary malignancy was non-melanoma skin cancer (6%).

Hepatotoxicity, Including Drug-Induced Liver Injury: Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including IMBRUVICA®. Evaluate bilirubin and transaminases at baseline and throughout treatment with IMBRUVICA®. For patients who develop abnormal liver tests after IMBRUVICA®, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold IMBRUVICA®. Upon confirmation of DILI, discontinue IMBRUVICA®.

Tumor Lysis Syndrome: Tumor lysis syndrome has been infrequently reported with IMBRUVICA®. Assess the baseline risk (e.g., high tumor burden) and take appropriate precautions. Monitor patients closely and treat as appropriate.

Embryo-Fetal Toxicity: Based on findings in animals, IMBRUVICA® can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA® and for 1 month after the last dose. Advise males with female partners of reproductive potential to use effective contraception during the same time period.

ADVERSE REACTIONS

The most common adverse reactions ($\geq 30\%$) in adult patients with B-cell malignancies were thrombocytopenia (55%)*, diarrhea (44%), fatigue (39%), musculoskeletal pain (39%), neutropenia (39%)*, rash (36%), anemia (35%)*, bruising (32%), and nausea (30%).

The most common grade ≥ 3 adverse reactions ($\geq 5\%$) in adult patients with B-cell malignancies were neutropenia (21%)*, thrombocytopenia (14%)*, pneumonia (8%), and hypertension (8%).

Approximately 9% (CLL/SLL) and 14% (WM) of adult patients had a dose reduction due to adverse reactions. Approximately 4%-10% (CLL/SLL) and 5% (WM) of adult patients discontinued due to adverse reactions.

*Treatment-emergent decreases (all grades) were based on laboratory measurements.

DRUG INTERACTIONS

CYP3A Inhibitors: Coadministration of IMBRUVICA® with strong or moderate CYP3A inhibitors may increase ibrutinib plasma concentrations. Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA® are recommended when used concomitantly with posaconazole, voriconazole, and moderate CYP3A inhibitors. Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA® if strong inhibitors are used short-term (e.g., for ≤ 7 days). Avoid grapefruit and Seville oranges during IMBRUVICA® treatment, as these contain strong or moderate inhibitors of CYP3A. See dose modification guidelines in USPI sections 2.3 and 7.1.

CYP3A Inducers: Avoid coadministration with strong CYP3A inducers.

SPECIFIC POPULATIONS

Hepatic Impairment (based on Child-Pugh criteria): Avoid use of IMBRUVICA® in patients with severe hepatic impairment. In patients with mild or moderate impairment, reduce recommended IMBRUVICA® dose and monitor more frequently for adverse reactions of IMBRUVICA®.

Please [click here](#) for full Prescribing Information.

References: 1. Burger J, Barr PM, Robak T, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA Library website. Published May 14, 2024. Accessed August 2, 2024. 2. IMBRUVICA® (ibrutinib) Prescribing Information. 3. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med*. 2015;373(25):2425-2437. 4. Data on file ABVRRIT77982 5. Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. *Blood Adv*. 2022;6(11):3440-3450. 6. Data on file ABVRRIT76502 7. Data on file ABVRRIT77315 8. Data on file ABVRRIT78305 9. Woyach JA, Barr PM, Kipps TJ, et al. Characteristics and clinical outcomes of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma receiving ibrutinib for ≥ 5 years in the RESONATE-2 study. *Cancers (Basel)*. 2023;15(2):507. doi:10.3390/cancers15020507 10. Data on file ABVRRIT76430


420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension

START AND STAY ON IMBRUVICA® FOR YOUR APPROPRIATE PATIENTS¹⁻⁴

Give your patients an opportunity to live longer and continue to experience the things they love^{2,3}

RESONATE™-2: primary analysis^{2,3}



SECONDARY ENDPOINT : HR=0.44 (95% CI: 0.21, 0.92); median follow-up of 28.1 months



PRIMARY ENDPOINT : HR=0.16 (95% CI: 0.09, 0.28; $P < 0.0001$); median follow-up of 18.4 months (IRC assessed)



The only BTKi with the longest follow-up data in 1L CLL/SLL¹

RESONATE™-2: 10-year long-term analysis^{1,4}

Median follow-up for patients in the IMBRUVICA® arm for all efficacy endpoints was 9.6 years (115.0 months [range 0.1–122.8]).^{1,4}

Most common ARs after 10 years: The most common ARs (all grades) occurring in $\geq 20\%$ of patients receiving IMBRUVICA® were diarrhea (52%), fatigue (41%), cough (39%), nausea (32%), arthralgia (31%), peripheral edema (31%), hypertension (30%), pyrexia (30%), upper respiratory tract infection (30%), pneumonia (29%), anemia (27%), urinary tract infection (26%), weight loss (25%), atrial fibrillation (24%), constipation (23%), vomiting (22%), back pain (21%), fall (21%), muscle spasms (21%), and dry eye (20%).⁴

Up to 10 years of follow-up^{1,4}



10-year RESONATE™-2 long-term efficacy results are not included in the Prescribing Information for IMBRUVICA®. The timing for long-term follow-up was not prespecified, and the analysis was descriptive in nature.

INDICATIONS

IMBRUVICA® is a kinase inhibitor indicated for the treatment of:

- Adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage; infections; cardiac arrhythmias, cardiac failure, and sudden death; hypertension; cytopenias; second primary malignancies; hepatotoxicity, including drug-induced liver injury (DILI); tumor lysis syndrome; and embryo-fetal toxicity.

ADVERSE REACTIONS

The most common adverse reactions ($\geq 30\%$) in patients with B-cell malignancies were thrombocytopenia (55%)*, diarrhea (44%), fatigue (39%), musculoskeletal pain (39%), neutropenia (39%)*, rash (36%), anemia (35%)*, bruising (32%), and nausea (30%).

*Treatment-emergent decreases (all grades) were based on laboratory measurements.

Please see complete Important Safety Information on pages 10-11 and [click here](#) for full Prescribing Information.

1L=first-line, AR=adverse reaction, BTKi=Bruton's tyrosine kinase inhibitor, CI=confidence interval, CLL=chronic lymphocytic leukemia, HR=hazard ratio, IRC=independent review committee, OS=overall survival, PD=progressive disease, PFS=progression-free survival, SLL=small lymphocytic lymphoma.

pharmacyclics
An AbbVie Company

Johnson & Johnson

imbruvica
(ibrutinib)

420, 280, 140 mg tablets | 140, 70 mg capsules
70 mg/mL oral suspension